p53 staining correlates with tumor type and location in sebaceous neoplasms

American Journal of Dermatopathology

Volumn 34, Issue 2, 2012, Pages 129-138

  Shalin, Sara C ^a   Sakharpe, Aniket ^b   Lyle, Stephen ^c   Lev, Dina ^b   Calonje, Eduardo ^d   Lazar, Alexander J ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

DNA mismatch repair; microsatellite instability; Muir Torre syndrome; p53; sebaceoma; sebaceous adenoma; sebaceous carcinoma

Indexed keywords

PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P53;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEBACEOMA; SEBACEOUS CARCINOMA; SEBACEOUS GLAND ADENOMA; SEBACEOUS GLAND DISEASE; SEBACEOUS GLAND HYPERPLASIA; SEBACEOUS GLAND TUMOR; TUMOR LOCALIZATION;

ADENOCARCINOMA, SEBACEOUS; ADULT; AGED; AGED, 80 AND OVER; DNA MISMATCH REPAIR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; SEBACEOUS GLAND NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84859104412     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3181ed39f9     Document Type: Article

References (42)

1. Cohen PR, Kohn SR, Davis DA, et al. Muir-Torre syndrome. Dermatol Clin. 1995;13:79-89.
2. Lachiewicz AM, Wilkinson TM, Groben P, et al. Muir-Torre syndrome. Am JClin Dermatol. 2007;8:315-319. (Pubitemid 47533559)
3. Pettey AA, Walsh JS. Muir-Torre syndrome: acase report and review of the literature. Cutis. 2005;75:149-155. (Pubitemid 40521809)
4. Mangold E, Pagenstecher C, Leister M, et al. A genotype-phenotype correlation inHNPCC: strong predominance of msh2 mutations in 41 patients with Muir-Torre syndrome. J Med Genet. 2004;41:567-572. (Pubitemid 38932119)
5. Ponti G, Losi L, Pedroni M, et al. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas. J Invest Dermatol. 2006;126:2302-2307. (Pubitemid 44413178)
6. Chhibber V, Dresser K, Mahalingam M. MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir-Torre syndrome. Mod Pathol. 2008;21:159-164. (Pubitemid 351172167)
7. Abdel-Rahman WM, Peltomaki P. Lynch syndrome and related familial colorectal cancers. Crit Rev Oncog. 2008;14:1-22; discussion 23-31.
8. Kruse R, Ruzicka T. DNA mismatch repair and the significance of a sebaceous skin tumor for visceral cancer prevention. Trends Mol Med. 2004;10:136-141. (Pubitemid 38293350)
9. Shalin SC, Lyle S, Calonje E, et al. Sebaceous neoplasia and the Muir-Torre syndrome: important connections with clinical implications. Histopathology. 2010;56:133-147.
10. Orta L, Klimstra DS, Qin J, et al.Towards identification of hereditary DNA mismatch repair deficiency: sebaceous neoplasm warrants routine immunohistochemical screening regardless of patient's age or other clinical characteristics. Am J Surg Pathol. 2009;33:934-944.
11. Singh RS, Grayson W, Redston M, et al. Site and tumor type predicts DNA mismatch repair status in cutaneous sebaceous neoplasia. Am J Surg Pathol. 2008;32:936-942.
12. Cesinaro AM, Ubiali A, Sighinolfi P, et al. Mismatch repair proteins expression and microsatellite instability in skin lesions with sebaceous differentiation: a study in different clinical subgroups with and without extracutaneous cancer. Am J Dermatopathol. 2007;29:351-358. (Pubitemid 47220485)
13. Benjamin CL, Ananthaswamy HN. p53 and the pathogenesis of skin cancer. Toxicol Appl Pharmacol. 2007;224:241-248. (Pubitemid 47575673)
14. Kruse JP, Gu W. Modes of p53 regulation. Cell. 2009;137:609-622.
15. Hall PA, McCluggage WG. Assessing p53 inclinical contexts: unlearned lessons and new perspectives. J Pathol. 2006;208:1-6. (Pubitemid 43025698)
16. Bolshakov S, Walker CM, Strom SS, et al. p53 mutations inhuman aggressive and nonaggressive basal and squamous cell carcinomas. Clin Cancer Res. 2003;9:228-234. (Pubitemid 36109738)
17. Gonzalez-Fernandez F, Kaltreider SA, Patnaik BD, et al. Sebaceous carcinoma. Tumor progression through mutational inactivation of p53. Ophthalmology. 1998;105:497-506.
18. McBride SR, Leonard N, Reynolds NJ. Loss of p21(WAF1) compart-mentalisation in sebaceous carcinoma compared with sebaceous hyperplasia and sebaceous adenoma. J Clin Pathol. 2002;55:763-766. (Pubitemid 35231908)
19. Cabral ES, Auerbach A, Killian JK, et al. Distinction of benign sebaceous proliferations from sebaceous carcinomas by immunohistochemistry. Am J Dermatopathol. 2006;28:465-471. (Pubitemid 44813616)
20. Kiyosaki K, Nakada C, Hijiya N, et al. Analysis of p53 mutations and the expression of p53 and p21WAF1/CIP1 protein in 15 cases of sebaceous carcinoma of the eyelid. Invest Ophthalmol Vis Sci. 2010;51:7-11.
21. Ren ZP, Ponten F, Nister M, et al. Two distinct p53 immunohistochemical patterns in human squamous-cell skin cancer, precursors and normal epidermis. Int J Cancer. 1996;69:174-179. (Pubitemid 26233294)
22. Dasgupta T, Wilson LD, Yu JB. A retrospective review of 1349 cases of sebaceous carcinoma. Cancer. 2009;115:158-165.
23. Rulon DB, Helwig EB. Cutaneous sebaceous neoplasms. Cancer. 1974; 33:82-102.
24. Troy JL, Ackerman AB. Sebaceoma. Adistinctive benign neoplasm of adnexal epithelium differentiating toward sebaceous cells. Am J Dermatopathol. 1984;6:7-13. (Pubitemid 14197489)
25. Nielsen TA, Maia-Cohen S, Hessel AB, et al. Sebaceous neoplasm with reticulated and cribriform features: a rare variant of sebaceoma. J Cutan Pathol. 1998;25:233-235. (Pubitemid 28188036)
26. Misago N, Mihara I, Ansai S, et al. Sebaceoma and related neoplasms with sebaceous differentiation: a clinicopathologic study of 30 cases. Am J Dermatopathol. 2002;24:294-304. (Pubitemid 34810304)
27. Nelson BR, Hamlet KR, Gillard M, et al. Sebaceous carcinoma. J AmAcad Dermatol. 1995;33:1-15; quiz 16-18.
28. Rutten A, BurgdorfW, Hugel H, et al. Cystic sebaceous tumors asmarker lesions for the Muir-Torre syndrome: a histopathologic and molecular genetic study. Am J Dermatopathol. 1999;21:405-413. (Pubitemid 29491265)
29. Abbott JJ, Hernandez-Rios P, Amirkhan RH, et al. Cystic sebaceous neoplasms inMuir-Torre syndrome. Arch Pathol Lab Med. 2003;127: 614-617. (Pubitemid 36534950)
30. Dinneen AM, Mehregan DR. Sebaceous epithelioma: areview of twentyone cases. J Am Acad Dermatol. 1996;34:47-50. (Pubitemid 26043926)
31. Seta T, Imazeki F, Yokosuka O, et al. Expression of p53 and p21WAF1/CIP1 proteins in gastric and esophageal cancers: comparison with mutations of the p53 gene. Dig Dis Sci. 1998;43:279-289. (Pubitemid 28124601)
32. Kazakov DV, Grossmann P, Spagnolo DV, et al. Expression of p53 and TP53 mutational analysis in malignant neoplasms arising in preexisting spiradenoma, cylindroma, and spiradenocylindroma, sporadic or associated with Brooke-Spiegler syndrome. Am J Dermatopathol. 2010;32:215-221.
33. Buitrago W, Joseph AK. Sebaceous carcinoma: the great masquerader: emgerging concepts in diagnosis and treatment. Dermatol Ther. 2008;21: 459-466.
34. Rao NA, Hidayat AA, McLean IW, et al. Sebaceous carcinomas of the ocular adnexa: a clinicopathologic study of 104 cases, with five-year follow-up data. Hum Pathol. 1982;13:113-122. (Pubitemid 12131097)
35. Goldberg M, Rummelt C, Foja S, et al. Different genetic pathways inthe development of periocular sebaceous gland carcinomas in presumptive Muir-Torre syndrome patients. Hum Mutat. 2006;27:155-162. (Pubitemid 43238031)
36. Jones B, Oh C, Mangold E, et al. Muir-Torre syndrome: diagnostic and screening guidelines. Australas J Dermatol. 2006;47:266-269. (Pubitemid 44536222)
37. Pfeifer GP, Besaratinia A. Mutational spectra of human cancer. Hum Genet. 2009;125:493-506.
38. Backvall H, Stromberg S, Gustafsson A, et al. Mutation spectra of epidermal p53 clones adjacent to basal cell carcinoma and squamous cell carcinoma. Exp Dermatol. 2004;13:643-650. (Pubitemid 39345274)
39. Backvall H, Wolf O, Hermelin H, et al. The density of epidermal p53 clones is higher adjacent to squamous cell carcinoma in comparison with basal cell carcinoma. Br J Dermatol. 2004;150:259-266. (Pubitemid 38352463)
40. Zanesi N Croce CM. Fragile histidine triad gene and skin cancer. Eur J Dermatol. 2001;11:401-404. (Pubitemid 32801333)
41. Becker K, Goldberg M, Helmbold P, et al. Deletions of BRCA1/2 and p53 R248W gain-of-function mutation suggest impaired homologous recombination repair in fragile histidine triad-negative sebaceous gland carcinomas. Br J Dermatol. 2008;159:1282-1289.
42. Ireland AP, Clark GW, DeMeester TR. Barrett's esophagus. The significance of p53 in clinical practice. Ann Surg. 1997;225:17-30. (Pubitemid 27026800)